🧬 Comprehensive DD on AbCellera (ABCL): From 2012 to 2025 – Full Analysis & Insights

Hey everyone,

I just finished putting together a deep-dive due diligence on AbCellera Biologics (ABCL), covering its entire journey from 2012 to today. This document includes:

• A detailed history of the company and its founder Carl Hansen
• Analysis of their business model and key partnerships
• Insights into their proprietary pipeline and royalty-bearing programs
• Financial performance and growth trajectory
• My personal perspective on their long-term potential

The goal was to create a thorough and objective resource for anyone interested in ABCL’s story and future prospects. I relied on a wide range of publicly available sources and, since English isn’t my first language, I also used AI assistance to refine the writing and ensure clarity.

If you find any factual inaccuracies or areas that could be improved, please let me know. I’ve been reviewing it multiple times, but I’d gladly update it based on community feedback.

📖 Here’s the full document (PDF): Comprehensive DD on AbCellera (2012–2025)

I hope you find it an interesting read and a solid starting point for discussion